Literature DB >> 31469293

Preeminent role of the cardiorenal axis in the antihypertensive response to an arteriovenous fistula: an in silico analysis.

John S Clemmer1, W Andrew Pruett1, Robert L Hester1,2, Thomas E Lohmeier1.   

Abstract

Percutaneous creation of a small central arteriovenous (AV) fistula is currently being evaluated for the treatment of uncontrolled hypertension (HT). Although the mechanisms that contribute to the antihypertensive effects of the fistula are unclear, investigators have speculated that chronic blood pressure (BP) lowering may be due to 1) reduced total peripheral resistance (TPR), 2) increased secretion of atrial natriuretic peptide (ANP), and/or 3) suppression of renal sympathetic nerve activity (RSNA). We used an established integrative mathematical model of human physiology to investigate these possibilities from baseline conditions that mimic sympathetic overactivity and impaired renal function in patients with resistant HT. After a small fistula was stimulated, there were sustained increases in cardiac output, atrial pressures, and plasma ANP concentration (3-fold), without suppression of RSNA; at 8 wk, BP was reduced 14 mmHg along with a 32% fall in TPR. In contrast, when this simulation was repeated while clamping ANP at baseline BP decreased only 4 mmHg, despite a comparable fall in TPR. Furthermore, when chronic resetting of atrial mechanoreceptors was prevented during the fistula, RSNA decreased 7%, and along with the same threefold increase in ANP, BP fell 19 mmHg. This exaggerated fall in BP occurred with a similar decrease in TPR when compared with the above simulations. These findings suggest that ANP, but not TPR, is a key determinant of long-term BP lowering after the creation of an AV fistula and support a contribution of suppressed RSNA if resetting of the atrial-renal reflex is truly incomplete.NEW & NOTEWORTHY The mechanisms that contribute to the antihypertensive effects of a small arteriovenous (AV) fistula comparable to the size used by the ROX coupler currently in clinical trials are unclear and not readily testable in clinical or experimental studies. The integrative mathematical model of human physiology used in the current study provides a tool for understanding key causal relationships that account for blood pressure (BP) lowering and for testing competing hypotheses. The findings from the simulations suggest that after creation of a small AV fistula increased ANP secretion plays a critical role in mediating long-term reductions in BP. Measurement of natriuretic peptide levels in hypertensive patients implanted with the ROX coupler would provide one critical test of this hypothesis.

Entities:  

Keywords:  AV fistula; arteriovenous anastomosis; atrial natriuretic peptide; blood pressure; physiological modeling; simulation

Mesh:

Substances:

Year:  2019        PMID: 31469293      PMCID: PMC7132311          DOI: 10.1152/ajpheart.00354.2019

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  45 in total

Review 1.  Long-term control of arterial blood pressure.

Authors:  A W Cowley
Journal:  Physiol Rev       Date:  1992-01       Impact factor: 37.312

2.  Effects of volume expansion on renal nerve activity, renal blood flow, and sodium and water excretion in conscious dogs.

Authors:  H Morita; S F Vatner
Journal:  Am J Physiol       Date:  1985-11

Review 3.  Diverse biological actions of atrial natriuretic peptide.

Authors:  B M Brenner; B J Ballermann; M E Gunning; M L Zeidel
Journal:  Physiol Rev       Date:  1990-07       Impact factor: 37.312

4.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.

Authors:  Melvin D Lobo; Paul A Sobotka; Alice Stanton; John R Cockcroft; Neil Sulke; Eamon Dolan; Markus van der Giet; Joachim Hoyer; Stephen S Furniss; John P Foran; Adam Witkowski; Andrzej Januszewicz; Danny Schoors; Konstantinos Tsioufis; Benno J Rensing; Benjamin Scott; G André Ng; Christian Ott; Roland E Schmieder
Journal:  Lancet       Date:  2015-01-23       Impact factor: 79.321

5.  Renal mechanisms for suppression of renin secretion by atrial natriuretic factor.

Authors:  D Villarreal; R H Freeman; J O Davis; K M Verburg; R C Vari
Journal:  Hypertension       Date:  1986-06       Impact factor: 10.190

6.  Time course of baroreceptor resetting in acute hypertension.

Authors:  E M Krieger
Journal:  Am J Physiol       Date:  1970-02

Review 7.  Role of atrial natriuretic peptide in long-term volume homeostasis.

Authors:  T E Lohmeier; H L Mizelle; G A Reinhart
Journal:  Clin Exp Pharmacol Physiol       Date:  1995-01       Impact factor: 2.557

8.  Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension.

Authors:  John Faul; Danny Schoors; Sofie Brouwers; Benjamin Scott; Andreas Jerrentrup; Joseph Galvin; Sandra Luitjens; Eamon Dolan
Journal:  J Vasc Surg       Date:  2014-01-28       Impact factor: 4.268

9.  Hemodynamic studies in DOCA-salt hypertensive rats after opening of an arteriovenous fistula.

Authors:  M Huang; R L Hester; A C Guyton; R A Norman
Journal:  Am J Physiol       Date:  1992-06

10.  Renal effects of ANP without changes in glomerular filtration rate and blood pressure.

Authors:  F J Salazar; M J Fiksen-Olsen; T J Opgenorth; J P Granger; J C Burnett; J C Romero
Journal:  Am J Physiol       Date:  1986-09
View more
  1 in total

1.  Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy.

Authors:  John S Clemmer; W Andrew Pruett
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-08-19       Impact factor: 5.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.